Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Why is the immune system unable to combat HIV? Key factor identified


An international research group with essential participation of the Paul-Ehrlich-Institut, has identified NLRX1, a cellular factor of the human cell that is indispensable to the replication of Human Immunodeficiency Virus (HIV-1). This factor plays a key role in attenuating the innate immune system towards HIV-1. Until now, the significance of NLRX1 for the replication of HIV-1 and the attenuation of the immune system was not known. The novel research finding will lead to new therapeutic approaches. The research results are reported in Cell Host Microbe in its oedition of 13.04.2016

HIV-1 uses human proteins (host proteins) for its own replication and prevents the human immune system from combating it successfully. Dr Renate König, head of the research group “Cellular Aspects of Pathogen Host Interactions” of the Paul-Ehrlich-Institut, and her colleagues have been studying this phenomenon for a long time, asking why the human immune system fails to fight HIV-1.

NLRX1 and HIV-1 infection a) NLRX1 attenuates immune reactions, thus enabling HIV replication. b) If NLRX1 is deactivated, the protective mechanisms can take effect and block HIV replication.

Source: PEI

To identify the underlying reason could help develop both enhancers for future efficacious vaccines and new immune-modulated HIV antivirals. The researchers have now reached one important milestone toward achieving this goal in an international research collaboration with Dr Jenny Ting, University of North Carolina at Chapel Hill, NC, USA, and Dr Sumit Chanda, Sanford-Burnham Prebys Medical Discovery Institute, San Diego, CA.

They have identified NLRX1 (nucleotide-binding oligomerization domain, leucine rich repeat containing X1) as an important factor. This protein belongs to the NOD-like receptor family (NOD-like receptors, NLR) of pattern recognition receptors. It acts as a fine-tuning regulator, which can deactivate the early warning system of the immune system. In a high-throughput procedure, NLRX1 had already been identified by König and colleagues as one out of 295 potential proteins important for HIV-1 replication [1]. The fact that it does play a central role, and which mechanisms it uses, has so far been unknown.

König and her international research partners provided evidence that NLRX1 enables HIV-1 infection in immune cells such as macrophages and dendritic cells (cells of the human immune system). The research team was able to show that NLRX1 attenuates the innate immune system by binding STING (stimulator of interferon genes). STING, an important factor in combating viruses, acts as a mediator. After (virus) DNA has been sensed by the receptor cGAS in the cytoplasm of the cells, STING binds to the factor TBK1 (TANK-binding kinase 1) and activates it.

Subsequently, type-I interferon and pro-inflammatory cytokines are produced. Moreover, the binding of STING to TBK1 leads to the activation of interferon-stimulating genes (ISG), which prevent the insertion of virus DNA into the nucleus of the cell, thus inhibiting its replication. These defense mechanisms are deactivated when NLRX1 binds to STING. By silencing NLRX, the researchers were able to show that this protein does indeed play a key role, because the cytokine response was considerably increased, thus inhibiting import of the virus DNA into the nucleus.

Therefore, NLRX1 is an attractive target structure for the development of therapies for the treatment of HIV-1. Advanced therapeutics, which block NLRX1 could also be used to act as adjuvants enhancing the efficacy of vaccines. “We believe that our research results can speed up the development of such active substances against HIV-1, which contribute to enhancing the innate immune response to HIV-1”, said König, explaining the significance of these research results.

Original Publication

Guo H, König R, Deng M, Riess M, Mo J, Zhang L, Petrucelli A, Yoh SM, Barefood B, Ventevogel M, Sempowski GD, Zhang A, Colberg-Poley AM, Feng H, Lemon SM, Liu Y, Zhang Y, Wen H, Zhang Z, Damania B, Tsao LC, Wang Q, Su L, Duncan JA, Chanda SK, Ting JPY (2016): NLRX1 Sequesters STING to Negatively Regulate the Interferon Response, Thereby Facilitating the Replication of HIV-1 and DNA Viruses.
Cell Host Microbe. Volume 19, Issue 4, p515–528

[1] König R, Zhou Y, Elleder D, Diamond TL, Bonamy GMC, Irelan JT, Chiang C, Tu BP, De Jesus PD, Lilley CE, Seidel S, Opaluch AM, Caldwell J, Weitzman MD, Kuhen KL, Bandyopadhyay S, Ideker T, Orth A, Miraglia LJ, Bushman FD, Young JA, Chanda SK (2008): Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication.
Cell 135: 49-60.

The Paul-Ehrlich-Institut, the Federal Institute for Vaccines and Biomedicines, in Langen near Frankfurt/Main is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). It is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and immunological veterinary medicinal products. Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects.

Other duties of the institute include official batch control, scientific advice and inspections. In-house experimental research in the field of biomedicines and life science form an indispensable basis for the manifold tasks performed at the institute.

The Paul-Ehrlich-Institut, with its roughly 800 members of staff, also has advisory functions nationally (federal government, federal states (Länder)), and internationally (World Health Organisation, European Medicines Agency, European Commission, Council of Europe etc.).

Weitere Informationen: - Abstract of the publication - Abstract of the Cell-Paper, mentioned in the press release - This press release on the PEI-Website

Dr. Susanne Stöcker | idw - Informationsdienst Wissenschaft

More articles from Life Sciences:

nachricht First time-lapse footage of cell activity during limb regeneration
25.10.2016 | eLife

nachricht Phenotype at the push of a button
25.10.2016 | Institut für Pflanzenbiochemie

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Etching Microstructures with Lasers

Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.

This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Ice shelf vibrations cause unusual waves in Antarctic atmosphere

25.10.2016 | Earth Sciences

Fluorescent holography: Upending the world of biological imaging

25.10.2016 | Power and Electrical Engineering

Etching Microstructures with Lasers

25.10.2016 | Process Engineering

More VideoLinks >>>